Collaboration with Salamanca University and the Institute of Neuroscience of Castilla y León to Study the Benefits of Cannabinoids on Epilepsy and Schizophrenia.
DENVER, December 18, 2018 – MJardin Group, Inc. (“MJardin” or the “Company”) (CSE:MJAR), a leader in cannabis management, today announced its first medical cannabis research investment to fund two studies on the benefits of cannabinoids on epilepsy and schizophrenia.